Navigation Links
Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
Date:9/12/2013

econd subject there was a transient suppression of VL at or below LOQ. The subject remains off ART.

A third subject completed the TI with 1-log decrease in VL from peak.
In three subjects, there was no reduction in VL during the TI, one completed the TI and in two the TI was terminated early due to their viral loads exceeding the upper limit allowed in the protocol.
A seventh subject has not completed TI and is still being evaluated.

The non-employee authors of these abstracts have no financial relationship with Sangamo.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and it has also established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic&re
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Acquire Ceregene
2. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
3. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
4. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
5. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
6. Sangamo BioSciences Reports First Quarter 2013 Financial Results
7. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
9. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
10. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
11. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... and BOSTON , May 29, 2015 ... development, custom automation, and contract manufacturing, and Vaxxas ... needle-free drug delivery technology, have been named winners of ... Nanopatch Jet Coating Instrument , an advanced technology ... product development.  The award was announced last evening at ...
(Date:5/29/2015)... May 29, 2015 /CNW/ - Covalon Technologies Ltd. (the ... technologies company, is delighted to announce its financial ... 2015, which includes revenue for three months of ... $264,340. Revenue from advanced wound care product sales for ... increased 24% to $1,742,672 compared to $1,400,065 for ...
(Date:5/29/2015)... VANCOUVER, British Columbia and ... DelMar Pharmaceuticals, Inc. (OTCQX: ... focused on developing and commercializing proven cancer therapies ... data at the American Association of Cancer ... on the potential for its lead product ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... U.S. Food and Drug Administration (FDA) has accepted for ... of Keppra XR(TM) (levetiracetam) in the, adjunctive ... ATLANTA, Jan. 16 UCB announced today that ... XR(TM) (levetiracetam) extended-,release tablets in the adjunctive treatment of ...
... rate from,cancer now is lower in older adolescents and ... because of a lack of access to clinical trials,nationally ... by pediatric,oncologists at Children,s Hospital of Pittsburgh of UPMC., ... with cancer have,improved dramatically over the last 30 years, ...
Cached Medicine Technology:Keppra XR(TM) Extended-Release Tablets Filed with the FDA 2Keppra XR(TM) Extended-Release Tablets Filed with the FDA 3Keppra XR(TM) Extended-Release Tablets Filed with the FDA 4Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 2Children's Hospital Cancer Study Finds Adolescents and Young Adults Don't Get Same Access to Cutting-Edge Treatment as Younger Patients 3
(Date:5/30/2015)... You've probably heard that using cotton swabs to clean the ... found a better way to remove ear wax? Luckily, a ... need. , They developed SUNDENG EAR CLEANER to ease the ... from the ears. What's more, it is safer and more ... today for children and adults of all ages. As such, ...
(Date:5/30/2015)... 30, 2015 The results of a ... has a high potential to cause mesothelioma, regardless of ... now on the Surviving Mesothelioma website. , ... Medicine in Lodz, Poland found that, among the 138 ... 1970 and 2012, all of them happened at plants ...
(Date:5/30/2015)... May 30, 2015 ProIntro Magnify contains 30 ... and animations. Instantly add an elegant opening title to any ... a range of clean design layouts. ProIntro Magnify is created ... is extremely easy to use. Simply drag a preset into ... on-screen-controls and parameters in the Inspector window then watch as ...
(Date:5/30/2015)... 30, 2015 At 73 years old, ... health , which she attributes to a lifetime of ... good nutrition with the release of her new book titled ... AU). , “Cook for Health and Longevity” features a collection ... mostly organic food . It is designed to encourage ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 ... today that she is offering a free analysis and ... The offer coincides with Disability Awareness Month, which was ... Industry members across the United States such as Polk ... to raise awareness about the possibility of disability, as ...
Breaking Medicine News(10 mins):Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... University of North Carolina (UNC) researchers report in the ... that narcotics and diagnostic testing are overused in treating ... more effective treatments for neck pain, such as therapeutic ... to support the effectiveness of therapeutic exercise in treating ...
... not considered effective treatment for KRAS (a gene)-mutated metastatic ... cancer not responding to chemotherapy and a certain variation ... longer overall and progression-free survival than patients with other ... issue of JAMA . "Recent retrospective ...
... 26 (HealthDay News) -- Older adults who survive severe sepsis ... with mental functioning, a new study indicates. This largely ... an increased burden on caregivers and families, as well as ... the researchers said. Also called "blood poisoning," sepsis is ...
... of Medicine and The Children,s Hospital have taken a big ... liver diseases in infants. The disease is called biliary ... which bile, crucial for digestion, flows to the small intestine. ... in 10,000 births. But it,s life-threatening. "It is ...
... , TUESDAY, Oct. 26 (HealthDay News) -- A new bivalent ... 1 and 3 -- triggers a stronger immune response than the ... vaccines, a new study shows. Use of trivalent and monovalent ... from more than 125 in 1988 to just four today. ...
... TUESDAY, Oct. 26 (HealthDay News) -- Dr. Alexander Heazell and his ... child in 2001. They planned to name him Jack. But ... pressure had shot up during the pregnancy, and at 26 weeks, ... baby was devastating for Heazell and his wife. The stress and ...
Cached Medicine News:Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2Health News:Brain Deficits Higher in Seniors Who Survive Blood Poisoning 2Health News:Breakthrough in understanding life-threatening childhood liver disease 2Health News:New Polio Vaccine Shows Major Advantages: Study 2Health News:Stillbirth Can Be Devastating, Unpredictable 2Health News:Stillbirth Can Be Devastating, Unpredictable 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron FS Ferene for determination of iron in serum. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P. For automated systems....
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
Medicine Products: